Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV
This article was originally published in The Pink Sheet Daily
Shionogi will clear up cash by turning over global rights to its integrase inhibitor portfolio to its joint venture partner in exchange for royalties and equity in ViiV.
You may also be interested in...
The launch of Tivicay, a once-daily integrase inhibitor, will be the driving force behind the HIV specialist’s return to growth, anticipated in 2014, according to CEO Dominique Limet.
The HIV specialist, a joint venture between GSK, Pfizer and Shionogi, will launch the once-daily integrase inhibitor Tivicay, priced slightly higher than Merck’s Isentress and about on par with Gilead’s Stribild when Tivicay is combined with backbone therapy.
Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning
TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)